JP3152433B2 - Ｈｉｖ感染防止用ワクチンおよび免疫療法剤 - Google Patents

Ｈｉｖ感染防止用ワクチンおよび免疫療法剤

Info

Publication number
JP3152433B2
JP3152433B2 JP51473190A JP51473190A JP3152433B2 JP 3152433 B2 JP3152433 B2 JP 3152433B2 JP 51473190 A JP51473190 A JP 51473190A JP 51473190 A JP51473190 A JP 51473190A JP 3152433 B2 JP3152433 B2 JP 3152433B2
Authority
JP
Japan
Prior art keywords
hiv
virus
siv
vaccine
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51473190A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05505389A (ja
Inventor
ディートリヒ、ウルズラ
アーダムスキイ、ミハリーナ
ブリーゼン、ハーゲン フォン
キューネル、ヘルベルト
リューブザーメン―ヴァイクマン、ヘルガ
Original Assignee
ヘモテラポイティッシェス・フォルシュングス インスティテュート・ゲオルグ・シュパイヤー―ハウス・ツー・フランクフルト・アー・エム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3152433(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヘモテラポイティッシェス・フォルシュングス インスティテュート・ゲオルグ・シュパイヤー―ハウス・ツー・フランクフルト・アー・エム filed Critical ヘモテラポイティッシェス・フォルシュングス インスティテュート・ゲオルグ・シュパイヤー―ハウス・ツー・フランクフルト・アー・エム
Publication of JPH05505389A publication Critical patent/JPH05505389A/ja
Application granted granted Critical
Publication of JP3152433B2 publication Critical patent/JP3152433B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP51473190A 1989-10-14 1990-10-12 Ｈｉｖ感染防止用ワクチンおよび免疫療法剤 Expired - Fee Related JP3152433B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE3934366.9 1989-10-14

Publications (2)

Publication Number Publication Date
JPH05505389A JPH05505389A (ja) 1993-08-12
JP3152433B2 true JP3152433B2 (ja) 2001-04-03

Family

ID=6391493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51473190A Expired - Fee Related JP3152433B2 (ja) 1989-10-14 1990-10-12 Ｈｉｖ感染防止用ワクチンおよび免疫療法剤

Country Status (8)

Country Link
US (1) US5861243A (enExample)
EP (1) EP0495896B1 (enExample)
JP (1) JP3152433B2 (enExample)
AT (1) ATE106748T1 (enExample)
DE (2) DE3934366A1 (enExample)
DK (1) DK0495896T3 (enExample)
ES (1) ES2055922T3 (enExample)
WO (1) WO1991005567A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047073A1 (en) * 1990-07-19 1992-01-20 William J. Leanza Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
CA2202408C (fr) * 1994-10-20 2012-03-06 Pierre Charneau Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
WO1998041657A1 (en) * 1997-03-20 1998-09-24 Affymetrix, Inc. Iterative resequencing
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
WO2006088740A2 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
DE68929467T3 (de) * 1988-06-14 2016-12-22 Qiagen Gmbh HIV-2 Varianten

Also Published As

Publication number Publication date
DE59006080D1 (de) 1994-07-14
EP0495896B1 (de) 1994-06-08
US5861243A (en) 1999-01-19
WO1991005567A1 (de) 1991-05-02
DK0495896T3 (da) 1994-10-10
DE3934366A1 (de) 1991-04-18
ES2055922T3 (es) 1994-09-01
JPH05505389A (ja) 1993-08-12
ATE106748T1 (de) 1994-06-15
EP0495896A1 (de) 1992-07-29
DE3934366C2 (enExample) 1991-11-07

Similar Documents

Publication Publication Date Title
US5861243A (en) Vaccine for protection against HIV infections, process for preparing same and their use as diagnostic and agent immunotherapeutic agent
Holmes et al. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.
Jin et al. Mosaic genome structure of simian immunodeficiency virus from west African green monkeys.
Naidu et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac
Cheng-Mayer et al. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation
Stivahtis et al. Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology
Gürtler et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon
Starcich et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
Yu et al. Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein
Fultz et al. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys).
CA2009403C (en) A packaging defective hiv provirus, cell lines, and uses thereof
Luciw et al. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac)
Desai et al. Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences.
Shioda et al. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus
Johnson et al. SIV infection of macaques as a model for AIDS pathogenesis
JPH08500965A (ja) ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
Kirchhoff et al. The" V3" domain is a determinant of simian immunodeficiency virus cell tropism
Ellenberger et al. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development
EP0478556A1 (en) Characterization of a replication competent human immunodeficiency type 2 proviral clone
Wyand The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines
Boeri et al. In vivo genetic variability of the human immunodeficiency virus type 2 V3 region
Franchini et al. Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects
Baier et al. Complete nucleotide sequence of a simian immunodeficiency virus from African green monkeys: a novel type of intragroup divergence
Shen et al. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence
WO1999004011A2 (en) Hiv-1 group o antigens and uses thereof

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees